Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2α

British Journal of Pharmacology

Volumn 117, Issue 6, 1996, Pages 1171-1180

  Krauss, Achim H P ^a   Woodward, David F ^a   Gibson, Linda L ^a   Protzman, Charles E ^a   Williams, Linda S ^a   Burk, Robert M ^a   Gac, Todd S ^a   Roof, Michael B ^a   Abbas, Farhat ^b   Marshall, Kay ^b   Senior, Judith ^b  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

AGN191976; AGN192093; Human platelets; Human uterus; Prostanoid receptors; Rat aorta; Smooth muscle; TP receptor heterogeneity; TxA2 mimetics; U 46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [7 (3 HYDROXY 1 OCTENYL) 3 OXO 2,4 DIOXABICYCLO[3.2.1]OCT 6 YL] 5 HEPTENOIC ACID; 7 [7 (3 HYDROXY 1 OCTENYL) 3 OXO 2,4 DIOXABICYCLO[3.2.1]OCT 6 YL] 5 HEPTENOL; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE CONTRACTION; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE; THROMBOCYTE; THROMBOCYTE AGGREGATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BLOOD PLATELETS; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDRAZINES; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PLATELET AGGREGATION; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, THROMBOXANE; THROMBOXANE A2; VASOCONSTRICTOR AGENTS;

EID: 0029918957     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16712.x     Document Type: Article

References (42)

1. 2 and histamine induced bronchoconstriction in man. Br. J. Clin. Pharmacol., 37, 97-100.
2. ARMSTRONG, R.A., JONES, R.L., PEESAPATI, V., WILL, S.G. & WILSON, N.H. (1985). Competitive antagonism at thromboxane receptors in human platelets. Br. J. Pharmacol., 84, 595-607.
3. 2α, in rabbit lung in situ. Am. J. Physiol., 263, H660-H663.
4. BUNDY, G.L. (1975). The synthesis of prostaglandin endoperoxide analogs. Tetrahedron Lett., 24, 1957-1960.
5. BURK, R.M., GAC, T.S., GARST, M.E., GIBSON, L.L., KRAUSS, A.H., PROTZMAN, C.E. & WOODWARD, D.F. (1994). Synthesis of a novel series of 3-oxo-2,4-dioxobicyclo[3.2.1]octanes: additional evidence for two thromboxane receptor subtypes. Bioorg. Med. Chem. Lett., 4, 2103-2106.
6. 2 on some isolated smooth muscle preparations. Br. J. Pharmacol., 73, 773-778.
7. COLEMAN, R.A., HUMPHREY, P.P.A., KENNEDY, I. & LUMLEY, P. (1984). Prostanoid receptors - the development of a working classification. Trends Pharmacol. Sci., 5, 303-306.
8. COLEMAN, R.A. & SHELDRICK, R.L.G. (1989). Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol., 96, 688-692.
9. DUNCAN, A.M.V., ANDERSON, L.L., FUNK, C.D., ABRAMOVITZ, M. & ADAM, M. (1995). Chromosomal localization of the human prostanoid receptor gene family. Genomics, 25, 740-742.
10. 2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. J. Pharmacol. Exp. Ther., 258, 74-81.
11. HARRIS, D.N., MICHEL, I.M., GOLDENBERG, H.J., HARTL, K.S., ALLEN, G.T., STEINBACHER, T.E., SCHUMACHER, W.A., HAN, W.C., HALL, S.E., FLOYD, D.M. & OGLETREE, M.L. (1992). Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552. J. Pharmacol. Exp. Ther., 261, 131-137.
12. 2 receptor. Nature, 349, 617-620.
13. JONES, R.L., PEESAPATI, V. & WILSON, N.H. (1982). Antagonism of the thromboxane-sensitive systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br. J. Pharmacol., 76, 423-438.
14. 2-mimetic, the actions of which are slowly reversed by receptor blockade. Br. J. Pharmacol., 96, 875-887.
15. KATSURA, M., MIYAMOTO, T., HAMANAKA, N., KONDO, K., TERADA, T., OHGAKI, Y., KAWASAKI, A. & TSUBOSHIMA, M. (1983). In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamino pinane derivatives). In Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 11. ed. Samuelsson, B., Paoletti, R. & Ramwell, P. pp. 351-357. New York: Raven Press.
16. KENNEDY, I., COLEMAN, RA., HUMPHREY, P.P.A., LEVY, G.P. & LUMLEY, P. (1982). Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins, 24, 667-689.
17. 2 receptor from rat astrocytes. Biochim. Biophys. Acta, 1265, 220-223.
18. 2/prostaglandin endoperoxide receptor antagonist. J. Cardiovasc. Pharmacol., 21, 441-447.
19. 2. Proc. Natl. Acad. Sci. U.S.A., 77, 1706-1710.
20. 2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br. J. Pharmacol., 97, 783-794.
21. 2 analogs in platelets and blood vessels. Eur. J. Pharmacol., 148, 309-315.
22. 2 receptors in platelets and blood vessels: evidence for different receptors. J. Pharmacol. Exp. Ther., 233, 418-424.
23. 2 receptors: Evidence for different subclasses in the rat. Biochem. Pharmacol., 42, 537-544.
24. MCKENNIFF, M., RODGER, I.W., NORMAN, P. & GARDINER, P.J. (1988). Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur. J. Pharmacol., 153, 149-159.
25. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins, 44, 155-163.
26. 2 receptor: cDNA cloning, expression and northern blot analysis. Biochem. Biophys. Res. Commun., 184, 1197-1203.
27. NARUMIYA, S., OKUMA, M. & USHIKUBI, F. (1986). Binding of radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br. J. Pharmacol., 88, 323-331.
28. 2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc. Natl. Acad. Sci. U.S.A., 76, 2566-2570.
29. NOREL, X., LABAT, C., GARDINER, P.J. & BRINK, C. (1991). Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. Br. J. Pharmacol., 104, 591-595.
30. 2 receptor gene. J. Biol. Chem., 268, 25253-25259.
31. OGLETREE, M.L., HARRIS, D.N., GREENBERG, R., HASLANGER, M.F. & NAKANE, M. (1985). Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther., 234, 435-441.
32. 3-receptor agonists on human isolated pulmonary artery. Br. J. Pharmacol., 113, 369-374.
33. 2 receptor. J. Biol. Chem., 269, 19256-19261.
34. SENIOR, J., MARSHALL, K., BAXTER, G.S. SANGHA, R. & CLAYTON, J.K. (1991). In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium. Br. J. Pharmacol., 102, 747-753.
35. SENIOR, J., SANGHA, R., BAXTER, G.S., MARSHALL, K. & CLAYTON, J.K. (1992). In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometrium. Br. J. Pharmacol. 107, 215-221.
36. 2 receptor using structurally different antagonists. Eur. J. Pharmacol., 152, 311-319.
37. 2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J. Biol. Chem., 265, 6836-6844.
38. 2 receptors. J. Clin. Invest., 90, 136-141.
39. 2 analogs and prostaglandins in isolated dog arteries. J. Cardiovasc. Pharmacol., 8, 818-825.
40. TOH, H., ICHIKAWA, A. & NARUMIYA, S. (1995). Molecular evolution of receptors for eicosanoids. FEBS Lett., 361, 17-21.
41. 2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Br. J. Pharmacol., 102, 607-614.
42. 2 receptor from human blood platelets. J. Biol. Chem., 264, 16496-16501.